APPLICATION OF ERYTHROPOIETIN THETA IN THERAPY OF ANEMIA IN ONCOLOGIC PATIENTS
https://doi.org/10.21518/2079-701X-2016-10-44-46
Abstract
Anemia is one of the most frequent complications arising in patients with malignant growths, it is characterized by reduction of hemoglobin level and disturbance of a number of physiological and metabolic processes in the organism, impairing the course of the disease and patients’ life quality. The major reasons of the hemoglobin concentration reduction include: anemia induction by the tumour, chemotherapy and chronic inflammation anemia. The most frequent methods of therapy are: red blood cell transfusion, prescription of erythropoiesis-stimulating drugs (ESA) and iron supplements. Erythropoietins indication is the most preferential method taking into account complications related to red blood cell transfusions. Erythropoetins alpha and beta are the most well-known and well-studied among the first generation ESAs. The erythropoietin theta is not a biological analogue. It is represented as a separate product. It demonstrated non-inferiority of anemia treatment in cancer patients as compared to the erythropoietin beta in studies. Dosage of 20 000 IU of erythropoietin theta was sufficient for the full hemoglobin response in more than a half of patients.
About the Authors
O. A. GLADKOV
EVIMED LLC
Russian Federation
Russian Federation
MD
Chelyabinsk
A. V. SNEGOVOY
Blokhin Russian Oncologic Scientific Center of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in medicine
Moscow
References
1. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. Eur J Cancer, 2004, 40: 2293-2306.
2. Liutkauskiene S, Janciauskiene R, Jureniene K, Grizas S, Malonyte R, Juozaityte E. Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients. BMC Cancer, 2015, 15: 105.
3. Anía B, Suman VJ, Fairbanks VF, Rademacher DM, Melton LJ 3rd. Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc, 1997, 45(7): 825-31.
4. M. Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and management of cancerrelated anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol, 2012, 23: 1954-1962.
5. Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother, 2013, 40(5): 302-9.
6. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B and for the Epoetin Alfa Study Group. Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double- Blind, Placebo-Controlled Trial. J Clin Oncol, 2001, 19: 2865-2874.
7. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, et al. and For the Aranesp™ 980297 Study Group. Double-Blind, Placebo- Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy. J Natl Cancer Inst, 2001, 94: 1211-1220.
8. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst, 2006, 98: 708-714.
9. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Kara J et al. Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia. JAMA, 2008, 299(8): 914-924.
10. Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis- timulating agents in tumor progression. Clin Cancer Res, 2011, 17(20): 6373-80.
11. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al., rythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev, 2012, 12, 12: CD003407.
12. Jelkmann W. Biosimilar epoetins and other «follow-on» biologics: Update on the European experiences. Am J Hematol, 2010, 85(10): 771- 780.
13. Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A. Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf, 2010 Sep, 3(3): 45-53.
14. Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A. Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf, 2011, 4(3): 33-41.
Review
For citations:
GLADKOV OA, SNEGOVOY AV. APPLICATION OF ERYTHROPOIETIN THETA IN THERAPY OF ANEMIA IN ONCOLOGIC PATIENTS. Meditsinskiy sovet = Medical Council. 2016;(10):44-46. (In Russ.) https://doi.org/10.21518/2079-701X-2016-10-44-46
Views:
713
Email this article 